Ipsen announced on July 22, 2026, that it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company. The transaction adds potravitug, a first-in-class monoclonal antibody, to Ipsen's Rare Disease pipeline. This acquisition aims to address BK polyomavirus (BKPyV) reactivation in kidney transplant recipients, a condition with significant clinical unmet needs.

Potravitug targets BKPyV reactivation and has demonstrated promising results in clinical trials. The Phase II SAFE KIDNEY II trial, the largest placebo-controlled study in this patient population, showed a significant anti-viral response and resolution of BKPyV-associated nephropathy. Additional analyses presented at international renal and transplant congresses have further supported its clinical profile.

BK polyomavirus is a common virus that remains inactive in most individuals but can reactivate in immunocompromised patients, such as kidney transplant recipients. Around 90% of these patients are positive for the BKPyV serotype, and approximately 30% experience high levels of the virus in the blood within the first year post-transplant. Reactivation can lead to serious consequences, including graft loss and the need for dialysis or re-transplantation. Currently, no approved targeted therapies exist for BKPyV, and clinical management relies on balancing graft protection with viral control through immunosuppression reduction.

The acquisition strengthens Ipsen's portfolio in Rare Disease, leveraging its nearly 100 years of development experience. Ipsen focuses on transformative medicines in Oncology, Rare Disease, and Neuroscience, with operations in over 40 countries and a presence in more than 100 countries.

Ipsen today announced positive topline results from its Phase III BEOND migraine program evaluating Dysport (abobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. Both the E-BEOND and C-BEOND trials met their primary endpoints, showing a reduction in monthly migraine days versus placebo. The results position Dysport as the first botulinum toxin to demonstrate efficacy in both episodic and chronic migraine prevention.

The E-BEOND results mark the first Phase III trial where a botulinum toxin has shown statistically significant efficacy in episodic migraine. Combined with the positive C-BEOND results, the BEOND program is the first to demonstrate efficacy of a botulinum toxin in preventing both episodic and chronic migraine. Dysport was well-tolerated across both trials, with safety findings consistent with its established profile and no new signals identified.

"These results represent a significant advance in the development of botulinum toxin therapies for migraine," said Christelle Huguet, PhD, EVP and Global Head of R&D at Ipsen. "BEOND is the first Phase III program to demonstrate efficacy of a botulinum toxin in both episodic and chronic migraine. Together, these findings position Dysport as a potential first-in-class treatment for a broad migraine population."

Trial Details

The BEOND Phase III program consisted of two randomized, multi-center, placebo-controlled trials: C-BEOND (NCT06047444) and E-BEOND (NCT06047457). The trials enrolled 1,510 patients across 120 centers. The primary endpoint for both trials was the change from baseline in the number of monthly migraine days at week 24, measured over weeks 21 to 24.

An Extension Phase of the BEOND trials, where all participants receive Dysport for two treatment cycles, will continue to week 48. Detailed findings from the program will be presented at a future scientific congress.

About Migraine and Dysport

Migraine is a complex neurological disease estimated to impact approximately 14% of the world’s population. Episodic migraine is defined as experiencing up to 14 headache days per month, with at least 6 being migraine days. Chronic migraine is defined as experiencing headaches on 15 or more days per month, with at least 8 migraine days.

Dysport (abobotulinumtoxinA) is an injectable form of botulinum neurotoxin type A. It inhibits the transmission of nerve impulses, reducing muscular contractions. AbobotulinumtoxinA has marketing authorization in approximately 90 countries, with more than 30 years of clinical experience and over 21 million treatment years of patient experience.